In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis
International Journal of Molecular Sciences · 18.03.2023 · 24 (6) · 5828
DOI: 10.3390/ijms24065828 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.03.2023. Verfasst von Toluwase Hezekiah Fatoki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Federal University Oye-Ekiti, PMB 373, Oye 371104, Nigeria. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs, Canada Research Chair.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is regarded as a fatal neurodegenerative disease that is featured by progressive damage of the upper and lower motor neurons. To date, over 45 genes have been found to be connected with ALS pathology. The aim of this work was to computationally identify unique sets of protein hydrolysate peptides that could serve as therapeutic agents against ALS. Computational methods which include target prediction, protein-protein interaction, and peptide-protein molecular docking were used. The results showed that the network of critical ALS-associated genes consists of ATG16L2, SCFD1, VAC15, VEGFA, KEAP1, KIF5A, FIG4, TUBA4A, SIGMAR1, SETX, ANXA11, HNRNPL, NEK1, C9orf72, VCP, RPSA, ATP5B, and SOD1 together with predicted kinases such as AKT1, CDK4, DNAPK, MAPK14, and ERK2 in addition to transcription factors such as MYC, RELA, ZMIZ1, EGR1, TRIM28, and FOXA2. The identified molecular targets of the peptides that support multi-metabolic components in ALS pathogenesis include cyclooxygenase-2, angiotensin I-converting enzyme, dipeptidyl peptidase IV, X-linked inhibitor of apoptosis protein 3, and endothelin receptor ET-A. Overall, the results showed that AGL, APL, AVK, IIW, PVI, and VAY peptides are promising candidates for further study. Future work would be needed to validate the therapeutic properties of these hydrolysate peptides by in vitro and in vivo approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Federal University Oye-Ekiti, PMB 373, Oye 371104, Nigeria.
- Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
- Faculty of Health Sciences, School of Nutrition Sciences, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
- Department of Chemistry and Biomolecular Sciences, Faculty of Science, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
- Richardson Centre for Food Technology and Research, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
ORCID-Profile: Toluwase Hezekiah Fatoki, Chibuike C Udenigwe, Rotimi E Aluko
Förderung
- Canada Research Chairs
- Canada Research Chair
Zitieren
APA
Fatoki, T. H., Chukwuejim, S., Udenigwe, C. C., & Aluko, R. E. (2023). In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 24(6), 5828. https://doi.org/10.3390/ijms24065828
Vancouver
Fatoki TH, Chukwuejim S, Udenigwe CC, Aluko RE. In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 2023;24(6):5828. doi:10.3390/ijms24065828
BibTeX
@article{Fatoki2023,
author = {Fatoki, Toluwase Hezekiah and Chukwuejim, Stanley and Udenigwe, Chibuike C and Aluko, Rotimi E},
title = {In Silico Exploration of Metabolically Active Peptides as Potential Therapeutic Agents against Amyotrophic Lateral Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5828},
doi = {10.3390/ijms24065828}
}
EUVIMED